Leadership Team

Brent Furse

CEO and President

Brent Furse has served as a Director and our Chief Executive Officer and President since June 2016. Prior to coming to VERO Biotech, Mr. Furse was a key member of the The Medicines Company leadership team where he joined in 2000 pre-IPO and served as a section 16 Officer.

He held various leadership positions including Executive Vice President, Chief Operating Officer, Chief Commercial Officer, Vice President and General Manager Interventional Medicine, Vice President Surgery and Perioperative Care, and Vice President of Sales and Marketing. He was responsible for the launch and success of their flagship product Angiomax, and countless successful partnerships and operational excellence. In addition to his success at The Medicines Company, Brent has held leadership positions with Centers for Disease Control, Bristol-Myers Squibb, and Schering Plough Corporation, and serves on the board of Anthera Pharmaceuticals, The Special Olympics and Salus Tele-health.

David Stocker

Chief Operating Officer

David Stocker joined Vero Biotech in 2016 and current serves as Chief Operating Officer. David Stocker delivers a unique blend of clinical and commercial operations skills and experience within the Healthcare Delivery and Bio Pharmaceutical industry.

In his 32 years of healthcare experience he has provided leadership at many levels, serving a diversity of customers and patients within many of the top 200 healthcare organizations in the US. David holds Doctor of Pharmacy and Master’s Degree in Health Administration from the University of Washington, and 2year Advanced Residency at Group Health Cooperative of Puget Sound in Seattle Washington. He has held senior level leadership positions in both the provider and commercial side of healthcare, in both a medical and commercial operations capacity. David has been credited with building and leading cross-functional teams that consistently deliver results by aligning innovative solutions with business goals, with substantial improvement to service delivery and business/system performance. David is a results oriented leader with proven success in strategic thinking, problem solving, and co-innovation with customers.

Marc Morin

Chief Financial Officer

Mr. Morin joined VERO Biotech as CFO in October of 2017, and has more than 15 years of experience in financial and executive management at emerging growth, life sciences, and global manufacturing companies.

Prior to VERO Biotech, Mr. Morin served as the CFO of Brookhaven Medical, Inc., a privately held holding company for medical device companies and medical technologies, and as the CFO of FutureMatrix Interventional, Inc., a privately held manufacturer and producer of high pressure PTA balloon catheters and urology devices. Previously, Mr. Morin served as the Global Controller of EndoChoice Holdings (Acquired by Boston Scientific), a publicly held medical device company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. During his tenure at EndoChoice, Mr. Morin oversaw all aspects of the finance, accounting, treasury and tax functions and helped the Company raise over $200 million in debt and equity financing, including over $100 million in its initial public offering. Prior to joining EndoChoice, Mr. Morin served as the Vice President of Finance and Accounting at Case-Mate, Inc., a privately held global leader in the design and manufacture of accessories for mobile devices. During his tenure at Case-Mate, Mr. Morin led the company’s international expansion into 7 countries and distribution of products in over 76 countries worldwide. Mr. Morin began his career at KPMG where he served a number of high growth public and private companies across a wide range of industries. He received an MBA from Emory University, a Masters of Accounting degree from Georgia State University, and a Bachelor’s of Accounting degree from St. Michaels’ College. He is also a licensed CPA in the state of Georgia.

Eric S. Finkelman

Chief Technical Officer

Mr. Finkelman has been an Operational and Product Development leader for over 25 years. He has led global teams in Operations, R&D and Customer Service. He combines a Growth-Oriented mindset with Lean Leadership methodologies to build systems and cultures that enable the development of People, Products and Processes.

Prior to joining VERO, Mr. Finkelman served as the V.P. of Global Operations and R&D at EndoChoice (Acquired by Boston Scientific). During his tenure, Mr. Finkelman oversaw all activities related to the Endoscopic Imaging platform, including direct oversight of the facilities in Germany and Israel. Previously, Mr. Finkelman served as the Vice President of Operations and R&D at Sierra Scientific Instruments, an NIH funded startup that became the global GI diagnostic industry leader in high-resolution manometry and reflux monitoring. During Mr. Finkelman’s tenure, the organization commercialized their flagship ManoScan and DigiTrapper platforms. This business was acquired by Given Imaging before subsequently becoming part of Medtronic. In prior positions, Mr. Finkelman held both Product Development and Operational leadership roles for both early stage private organizations and larger public companies. Mr. Finkelman holds a B.S. in Mechanical Engineering from Rensselaer Polytechnic Institute and a M.S. in Manufacturing Engineering from the University of Southern California.

Namita Khanna

Vice President of Strategic Development

Namita is a successful senior-level business leader driving more than two decades of exceptional results focused on sales, business development, and account management across diverse markets including healthcare, finance, and hospitality.

She is strategic and multidisciplinary with an eye for innovation, positioning, and relevance. She has worked for a wide array of Fortune 500 firms such as American Express, Marriott International, and Eli Lilly and Company.

Namita attended Widener University in Philadelphia obtaining an undergraduate degree in Hospitality Management and Marketing. Following an International feasibility project, she began her career in the Marriott Executive Sales Training Program working in New York and the Washington DC area. Namita then went back to school for Investment education and received her Series 6, 7, 63, 65, and all relevant financial licenses to begin working as a Financial Investment Planner with American Express in Washington DC and then Atlanta. After starting and working in a successful group practice in Atlanta, she transitioned to the Pharmaceutical Industry and worked in hospitals and institutions for 17 years from New Jersey, to Atlanta, to Orlando for Eli Lilly and Company. After a three-year period with an acute care hospital-based company named The Medicines Company, Namita created her own consulting firm and is currently working as Vice President Strategic Development for VERO Biotech.

Michelle Nickoli

Vice President of Customer Engagement

Michelle joins VERO Biotech Sales team for the launch of the Genosyl DS. She is a healthcare and patient-centric business professional with over twenty-two years experience in building positions driven by quality and results.

Ms. Nickoli brings a track record of demonstrated consistent achievement of organizational goals, strong sales and performance/quality objectives. Michelle is a Registered Respiratory Therapist and holds a Bachelors Degree in Sales and Marketing. She started her career as an RRT at Bellin Hospital and Aurora HealthCare before moving into the medical device industry at Possis Medical and pharmaceutical industry with The Medicines Company and Melinta Therapeutics. Michelle has built and lead several successful customer facing teams for 10 acute care product launches in various therapeutic areas such as infectious diseases, surgical, emergency medicine and cardiovascular. Her passion for presenting patient focused messages is invaluable in leading and bringing teams to action that result in completion of common goals.

Jason White

Vice President of Research and Development

Jason White is Vice President of Research and Development for VERO Biotech, LLC. Over the past 20 years, he has demonstrated leadership in developing and commercializing complex medical technologies for the treatment of cardiovascular and pulmonary diseases.

Before VERO Biotech, Jason served as Vice President of Research and Development for CardioMEMS Inc. and Sr. Director of Product Development for St. Jude Medical, Inc. During 15 years with CardioMEMS/St. Jude Medical, Jason led Research and Development for the CardioMEMS HF System, the first commercialized wireless implanted monitor which was clinically proven to improve care for heart failure patients living outside the hospital. Upon commercialization of the CardioMEMS System in June 2014, St. Jude Medical, Inc. acquired the company and he continued to lead development of next generation CardioMEMS systems. Prior to CardioMEMS and St. Jude Medical, Jason led product development teams for next generation angioplasty catheters and stents for Cordis, a Johnson and Johnson company. Jason holds a BSE in Biomedical and Electrical Engineering from Duke University, and a MS in Engineering Management from Florida International University.

Mike Gentile

Vice President of Medical Affairs

Mike Gentile has been involved with Respiratory and Critical Care for 30 years. Mr. Gentile is active in research, administration, teaching and clinical practice. He has been awarded fellowships from the American Association for Respiratory Care and American College of Critical Care Medicine. Mike is a content expert in many areas of cardiopulmonary physiology resulting in over 100 peer-reviewed abstracts, manuscripts and textbook chapters. He has been involved in the research, development, testing, training and launch of many devices and methods used in current clinical practice.

Lindsey M Peterson

Vice President of Human Strategies

Lindsey M Peterson has served as Vice President of Human Strategies since June 2019. Prior to serving in her current role, Ms. Peterson was the Company’s Corporate Controller since November 2017. Prior to joining VERO Biotech, Ms. Peterson served as Corporate Controller of Brookhaven Medical, Financial Reporting Manager at Bluegreen Vacations (ticker “BXG”), and Assurance Manager at EY.

As Vice President of Human Resources, Ms. Peterson is responsible for creating ways to engage all employees and establishing culture that will development leaders and empower employees to solve problems. She is instrumental in integrating human resource initiatives into the strategic goals of VERO Biotech. Lindsey possesses experience in several aspects of human resources including: recruitment, incentives, performance management, benefits and payroll.
Ms. Peterson has been a dynamic human resource practitioner with extensive experience in financial reporting, data analysis, and auditing of both publicly traded and private companies. Her industry expertise includes life sciences, healthcare, hospitality, and real estate. She graduated from the University of South Florida with a Bachelor of Science in Accounting and is a licensed Florida Certified Public Accountant.

INDICATION & IMPORTANT SAFETY INFORMATION

GENOSYL^® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
Methemoglobin, NO2, and PaO2 should be monitored during nitric oxide administration.
In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema.
The most common adverse reaction is hypotension.
Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
See package insert for additional Important Safety Information.

Brent Furse

David Stocker

Marc Morin

Eric S. Finkelman

Namita Khanna

Michelle Nickoli

Jason White

Mike Gentile

Lindsey M Peterson

Contact Info

Quick Links

Medical Inquiries

ANAB Accredited